Aura Biosciences develops bel sar, an experimental cancer drug for eye and bladder tumors that is still in clinical trials. AURA reports earnings on Thu, Nov 5, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 11 | HC Wainwright & Co. | Maintained | Buy | |
| Nov 26 | Evercore ISI Group | Reinstated | Buy |
Seasonality
How AURA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in AURA in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AURA is in one of them and how their past AURA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AURA in an article yet. Here's the latest on the wider market.
About Aura Biosciences
Aura Biosciences is a biotechnology company developing drugs to treat solid tumors while aiming to preserve organ function. Its lead candidate, bel sar, is in later stage clinical trials for early choroidal melanoma, a rare eye cancer, and is also being tested in other eye cancers and in bladder cancer. Bel sar is built from modified human papilloma virus proteins linked to molecules that are activated by light, and it has not yet been approved for sale. The company is based in Boston, Massachusetts, and its intended patients are adults with these cancers.
- Headquarters
- Boston, MA